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present a method for conducting CUA and CBA based in
conjoint analysis. Using conjoint analysis for CBA, as op-
posed to other methods such as contingent valuation, has
the advantage of allowing a researcher to easily compute
the monetary value for a range of outcomes. CUA analy-
ses conducted using conjoint analysis allow a researcher
to estimate not only overall changes in patient utility re-
sulting from an intervention, but also changes in utility
resulting from changes in any of a number of attributes
of the intervention, such as mode of administration or
dosing frequency. We illustrate the use of the conjoint
analysis methodology to conduct CBA and CUA using
data from two pilot studies. We will conclude the work-
shop with an interactive discussion of the relative merits
of these different approaches.
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OBJECTIVES: This workshop will describe the strategic
value of including productivity measures as outcomes of
concern in clinical trials, burden of illness studies, and
post-marketing research.
PARTICIPANTS WHO WOULD BENEFIT: Sponsors of
clinical trials, burden of illness studies, and post-market-
ing research; Employers who offer medical care benefits
and other benefit programs; Outcomes researchers; Drug
formulary developers; Regulators.
Until recent years, productivity has been overlooked as a
measure of value in clinical trials, burden of illness stud-
ies, and post-marketing research. However, recent ad-
vances in data development capabilities and market pres-
sures to differentiate the plethora of drugs either under
development or on the market have motivated a concern
for a broader set of relevant outcome measures. In addi-
tion, concerns over the ability to document the total im-
pact of drug therapy have emerged as important issues, as
pharmaceutical developers, health care providers, em-
ployers, formulary developers, and policy-makers strive
to fully understand their own or society’s return on
investment in drug therapy. Recent evidence suggests
that, among leading employers in the U.S., productivity-
related metrics account for more than half (53%) of the
cost of employer benefit programs. In Europe, rigorously
developed and supportable claims about the impact of
drugs under development or already marketed can influ-
ence the drug approval process. In the U.S. and else-
where, such evidence may influence initial and subse-
quent formulary decisions, and the appropriate use of
alternative drug therapies. This workshop will illustrate
how to 1) identify productivity-related metrics, 2) collect
and process data on these metrics, and 3) use these data
in sophisticated research studies designed for clinical tri-
als, to document the full burden of illness, or to legiti-
mately support post-marketing claims of the effectiveness
of drug therapy. It will be shown that metrics related to
morbidity, mortality and quality of life that are typical in
many research studies are incomplete, and that better de-
cisions can be made by incorporating a more complete set
of relevant outcome measures.
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OBJECTIVES: Use of claims data in pharmacoeconomic
analyses presents numerous challenges to the researcher.
A prominent issue is how to assemble discrete service
items (visits, tests, drugs, etc.) into clinically coherent epi-
sodes of care, and thereby quantify the costs of a given
illness. The objective of this workshop is to explore meth-
ods for constructing episodes of care, with illustrations
drawn from the Episode Treatment Group (ETG) meth-
odology widely employed in managed care.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers who are involved in the design and implementation of
claims-based pharmacoeconomic and outcomes research.
Claims data obtained from managed care organizations
and other health insurers provide a rich resource for in-
vestigating costs of illness and treatment outcomes. Be-
cause these data are collected to support provider reim-
bursement, each service rendered to a patient is itemized.
The use of these data for research requires a methodology
for determining which service items and costs are rele-
vant to the disease and/or treatment of interest. For ex-
ample, if a patient visits a doctor for a given illness, are
all laboratory tests and procedures ordered at that visit
considered related to that illness? If the physician records
more than one diagnosis, how are the costs of the visit
apportioned to each illness? Since pharmacy claims have
no diagnoses, how can drugs be linked to diseases? In
acute illness, how long is the episode of care and how are
recurrent episodes distinguished from prolonged single
episodes? Development of appropriate algorithms re-
quires both clinical and economic judgment, as well as an
understanding of the reimbursement system that has gen-
erated the data. The workshop will present general ap-
proaches with examples drawn from a number of acute
and chronic diseases. The Episode Treatment Group
(ETG) methodology widely used in managed care will be
presented as a relevant example of episode grouping
logic.
